# The Effect Of Ticagrelor On Saphenous Vein Graft Patency In Patients Undergoing Coronary Artery Bypass Grafting Surgery

Study · id `cardio:ct-nct02352402` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02352402](<https://clinicaltrials.gov/study/NCT02352402>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02352402

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 487 participants.

## Technical summary

Registry record NCT02352402. Randomized; quadruple masking; primary purpose treatment. Start 2015-03 (registry gives no type); primary completion 2020-08 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 487 participants (planned count; ClinicalTrials.gov record NCT02352402, source copy `cardio:ctgov-nct02352402-2020-04-27`, retrieved 2026-10-26)
- Start date: 2015-03 (registry gives no type) (ClinicalTrials.gov record NCT02352402, source copy `cardio:ctgov-nct02352402-2020-04-27`, retrieved 2026-10-26)
- Primary completion: 2020-08 (anticipated) (ClinicalTrials.gov record NCT02352402, source copy `cardio:ctgov-nct02352402-2020-04-27`, retrieved 2026-10-26)
- Completion: 2020-08 (anticipated) (ClinicalTrials.gov record NCT02352402, source copy `cardio:ctgov-nct02352402-2020-04-27`, retrieved 2026-10-26)
- Countries: Netherlands (ClinicalTrials.gov record NCT02352402, source copy `cardio:ctgov-nct02352402-2020-04-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02352402-2020-04-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Effect Of Ticagrelor On Saphenous Vein Graft Patency In Patients Undergoing Coronary Artery Bypass Grafting Surgery
- Acronym: POPular CABG
- Condition: Coronary Artery Disease
- Condition: Stable Angina
- Condition: Acute Coronary Syndrome
- Intervention (Drug): Ticagrelor
- Intervention (Drug): Placebo
- Lead sponsor: J.M. ten Berg
- Lead sponsor class: OTHER
- Collaborator: AstraZeneca
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Stable angina (`cardio:stable-angina`)
- Registry intervention name matches this record: Ticagrelor (`cardio:ticagrelor`)
- Registry intervention is a member of this class by a sourced record link: P2Y12 inhibitors (drug class) (`cardio:p2y12-inhibitors`)
- Registry lists this organization as a collaborator: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: dc30db0147e4a76b67d89f71f1b2916fed53978c9bb7c5febcc14cc4f327c5dc
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
